



A development of a new drug is an extremely complex process, with average costs over $900 million and a time span up to 15 years. Regulatory 
hurdles are progressively higher, costs are escalating and the competition is ever tougher. All these factors drive pharmaceutical companies to shor-
ten the Research & Development (R&D) process as much as possible. Consequently, methodologies for increasing productivity of the R&D processes 
become more and more important. One of them, a linear drug discovery paradigm starts from numerous genes and ends with prospective drugs. It 
consists of four inter-related building blocks that together provide a whole new platform that drives a focus on R&D e6 orts and commercial capabi-
lities, on use of product and capability partnerships, on provision of customer solutions (prevention, prediction and follow-up, not just treatment), 
and 7 nally on preference of organizations based on a business unit model instead of a functional one. Companies are to 7 nd a combination of these 
building blocks that best 7 ts their strengths, improves returns and minimizes involved risks.
Predictive methodology, together with other prediction approaches applied in drug discovery, is powerful tool that is quickly becoming more and 
more important, if not essential, in modern drug development. In this review, a brief description of new trends, as well as new challenges of today’s 
drug discovery is presented from the insider perspective.
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Review
Challenges of today’s drug development 
process
The pharmaceutical industry is facing unprece-
dented challenges to its current business model. 
Independent observers and industry analysts have 
also predicted its forthcoming signi; cant decline 
(1). It is obvious that certain changes are long over-
due if this industry is to meet investors’ expectati-
on and at the same time come up with viable an-
swers to unmet medical needs, i.e. successful trea-
tments of currently incurable diseases.
Large pharmaceutical companies will need to in-
vent new approaches and methodologies just in 
order to maintain their present status. First, they 
have to decide on what areas they should focus 
on, given their unique capabilities and strategic 
assets. Second, in order to pro; tably develop and 
market drugs they will need to explore new areas 
of science and include targeted customer groups 
at the early phase of a drug R&D process. Third, 
upon a decision what is their main focus, they will 
need to identify all the key capabilities necessary 
to achieve their goals, and to build or retain speci-
; c capacities that will give them signi; cant advan-
tages over their competition. They will also need 
to ; gure out where they can pro; tably add value 
for patients beyond just providing drugs. But, to 
obtain all this they will subsequently have to re-
structure their organizations to speed up the ove-
rall decision-making process, increase accountabi-
lity and reduce overall cost (2).
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All these changes will lead to the introduction of 
new market segments, besides the currently most 
explored market segment of treatment. The newly 
evolving market opportunities are mainly concen-
trated around following market segments – pre-
vention, prediction, patient’s participation and 
personalization of medical approach and therapi-
es. However, we should always bear in mind the 
ever-present and very important market segment 
of a drug follow-up. This trend has been already 
announced more than ten years ago by key anal-
ysts, but was never seriously considered so far (Fi-
gure 1).
Implementation of this approach in routine work 
practice was a major challenge for the drug disco-
very industry over the last decade. However, the 
exploration of new development opportunities is 
a must for today’s pharmaceutical businesses, sin-
ce this represents a key element in the overall R&D 
cycle time reduction and resource preservation.
Improvement of R&D process
Reductions in R&D cycle time can be achieved in 
many ways. However, in less predictable systems, 
such as pharmaceutical R&D, approaches to cycle 
time reduction cannot be simply adopted as in 
predictable systems like production, although 
principles behind these methodologies have alre-
ady been applied to some extent in drug manu-
facturing systems (3).
Considerations for reducing the cycle time of each 
phase of drug discovery and development are qui-
te often project and phase speci; c. Each phase of 
development consists of a collection of unit proce-
sses, or individual tasks that consume time and re-
sources. The sequential arrangement of these ta-
sks can often be unique to an individual research 
project, exhibiting a signi; cant variability introdu-
ced by the type of the science associated with 
every R&D project. Because of this inherent varia-
bility, cycle time reduction at a macro level can be 
achieved through task- and project-speci; c inter-
ventions aimed at reducing non-value added tasks 
and lag-times associated with completion of value 
added tasks. The role of an experienced project 
manager, assuming the commitment of his/hers 
project team, is crucial for the successful and time-
ly completion of pre-de; ned milestones along an 
R&D process.
There are few key approaches identi; ed for the re-
duction of project-speci; c cycle times, but the 
most important one is the portfolio selection. 
When selecting the R&D projects portfolio, the 
consideration of overall project cycle time should 
be also an instrument for reducing overall costs. 
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FIGURE 1. Signi; cant new market opportunities were opening up which expanded the role of the large pharmaceutical companies in 
the healthcare chain (modi; ed from the last PricewaterhouseCoopers (PwC) business report from the 20th century).
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For example, a cycle time of pivotal clinical trials is 
often a function of the disease state or a pursued 
indication itself.
The common approach is to reduce the attrition 
rate at advanced pre-clinical or clinical phases of 
drug development. This can be achieved by detec-
ting as early as possible all the key factors that co-
uld be the reasons for withdrawals from market 
because of unmet safety or e  ̂ cacy speci; cations. 
In this respect, predictive techniques and appro-
aches are of great help for pharmaceutical sci-
entists.
Predictive tools in early R&D process phases
In general, the e  ̂ cacy of the candidate drugs can 
be unsatisfactory because of many reasons, but 
some factors are easier to avoid than the others. In 
general, poor oral bioavailability and pharmacoki-
netic properties are among the most cited reasons 
for stopping a drug development process. In addi-
tion, toxicity issues, which were not predicted by 
in vitro modeling as well low e  ̂ cacies observed in 
later animal pharmacology models, are often rea-
sons for eliminations of a lead compound develo-
pment. Preclinical ADMET (absorption, distributi-
on, metabolism, excretion and toxicity) studies can 
help in increasing attrition rates in early clinical 
phases Phase I (healthy volunteers, mainly safety 
studies) and Phase IIa (preliminary e  ̂ cacy studies 
on a small number of patients) (4).
Given their highly speci; c target-binding charac-
teristics, fully human or humanized monoclonal 
antibodies have greatly reduced o  ̀-target toxicity 
compared to small molecules (5). Similar approach 
to reduce the attrition rate in later phases is to de-
velop targeted therapies for validated targets.
A search for a cost-e  ̀ective approach that can pre-
dict toxicological liabilities or other undesirable 
ADME (absorption, distribution, metabolism, 
excretion) properties during the pre-clinical phase 
(especially for small chemical molecules, molecu-
lar weight ≤ 500 Da) is a paramount for all pharma-
ceutical companies as this would be a clear break-
through in reducing the downstream attrition. All 
major pharmaceutical companies are pursuing this 
holy grail of the drug development (6). In fact, the 
number (and percentage) of drug candidates su-
ccessfully entering Phase I has increased recently 
(7), in part due to a better preclinical characteriza-
tion with improved ADMET properties and becau-
se of the use of wisely designed pharmaco-dyna-
mics models during the early phases of drug deve-
lopment (8). Modeling and predicting pharmaco-
logical properties of molecules, like solubility, toxi-
city or blood-brain-barrier penetration is extreme-
ly important in both drug design and drug develo-
pment. Modeling and prediction can improve our 
understanding of chemical and physical mechani-
sms behind these key properties and provide tools 
for predicting their values for molecules that are 
not yet synthesized. The group of scientists at In-
stitute is developing new methods for predicting 
ADMET properties (9-11). Their project started as a 
collaboration with a pharmaceutical industry and 
it is worth mentioning that it‘s results were so va-
luable because of a carefully planned and perfor-
med in vitro and in vivo experiments that provided 
the relevant and accurate data. This data was later 
used for testing and validation of developed mat-
hematical models and prediction tools.
Predictive approach in advanced R&D phases
Going further toward the late stages of drug deve-
lopment, Phase II and Phase III attrition rates rema-
in unacceptably high: 52% and 29%, respectively, 
based on the most recent benchmarking estima-
tes (Figure 2) (12). Phase II attrition rate in particu-
lar have not improved substantially since those re-
ported for the 1991–2000 period. At that time 62% 
attrition rate was reported for the Phase II and 45% 
for the Phase III. However, there are certain thera-
peutic areas that exhibit even higher attrition rates 
like neurology and gastroenterology (13).
There are two key approaches to reduce Phase II 
and III attrition, which should ideally be carried out 
jointly (as noted by a number of authors) (14):
the ; rst is a better target selection (identi; cati-• 
on of validated and “druggable” targets);
the second is a routine pursuit of early “proof of • 
concept” clinical studies, especially in Phase I, 
for which biomarkers and surrogate endpoints 
can often be employed.
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Early target selection and identi; cation of ; rst pro-
mising hits, combining in silico and biological 
screening is certainly one way for carrying out ini-
tial research for the new chemical entities in 
today’s pharmaceutical industry (15). This method 
synergistically combines synthetic chemistry, in vi-
tro screening and computational drug design 
approaches in order to provide added value to 
compounds already existing in the depository or 
compounds bank of research institutes associated 
to pharmaceutical industry (16,17).
To optimize biomarker development and capture 
value, it is an imperative to ensure that biomarkers 
are developed early and that they are commerci-
ally available at the time of the drug launch (18).
One way to reduce development costs is to tailor 
therapies to speci; c patient population, as illustra-
ted by the development of imatinib (Gleevec; No-
vartis) (19) or to stratify patient populations for 
both clinical development and commercialization, 
as in trastuzumab example (Herceptin; Genente-
ch/Roche) (20).
It was predicted that advances in genomics and 
proteomics, including those resulting directly from 
the sequencing of the human genome, would yield 
an abundance of drug targets (21). However, althou-
gh many new potential drug targets have been 
identi; ed by these approaches, far too few have 
been su  ̂ ciently validated so far to have any impact 
on the pharmaceutical R&D. Nevertheless, we belie-
ve that in the very near future a use of validated 
drug discovery targets will be the way to succeed.
In this respect, it is crucial to strengthen the link 
between genomics, proteomics, biochemistry and 
the clinics in order to predict, as soon as possible, 
pharmacological response (22).
In addition, as a conclusion, enabling a wide range 
of synergies through connection of research gro-
ups from the educational, clinical and pharmaceu-
tical sectors by establishing translational medicine 
centers will encourage translational research and 
translational medicine implementation. In this 
way, interaction of highly educated research sta  ̀, 
research support services, specialized experts in a 
multidisciplinary, trans-disciplinary and interdisci-
plinary environment will have a signi; cant impact 
on improvement of general health and the higher 
quality of life.
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FIGURE 2. Chances of failure, attrition rates, during the drug development process; source: The Trufts Center for drug Development, 
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Prediktivne metode kao uspješan alat u otkrivanju lijekova
Sažetak
Razvoj novog lijeka vrlo je kompleksan proces koji u prosjeku stoji više od 900 milijuna američkih dolara te traje i do 15 godina. Regulativne za-
preke su progresivno sve veće, troškovi sve viši, a konkurencija nije bila nikada jača. Svi ti čimbenici tjeraju farmaceutske kompanije na što veće 
skraćenje procesa istraživanja i razvoja (engl. Research & Development, R&D). Kao posljedica toga, metodologije koje povećavaju produktivnost 
procesa istraživanja i razvoja postaju sve značajnije. Jedna od njih, linearna paradigma otkrivanja lijekova, polazi ispitivanjem brojnih gena te kao 
rezultat daje budući lijek. Sastoji se od četiri međusobno povezana elementa koji tako povezani pružaju potpuno novu platformu, koja težište 
stavlja na rezultate procesa istraživanja i razvoja te komercijalne mogućnosti, na primjenu proizvoda i partnerstva, na pružanje rješenja krojena 
prema korisniku (prevencija, predviđanje i praćenje, a ne samo liječenje) te na prednosti organizacijske sheme temeljene na modelu poslovne 
jedinice, a ne na modelu funkcionalne jedinice. Kompanije trebaju pronaći pravu kombinaciju tih elemenata, onu koja najbolje odgovara njihovim 
jačim stranama, poboljšava pro7 t i minimalizira prisutan rizik. Pristupi prediktivne metodologije, zajedno s ostalim prediktivnim pristupima, koji 
se rabe pri otkrivanju lijeka predstavljaju uspješno sredstvo koje velikom brzinom postaje sve važnije, pa čak i ključno u današnjem modernom 
razvoju lijekova. U ovom ćemo pregledu dati kratak opis novih trendova kao i nove izazove današnjeg razvoja lijekova.
Ključne riječi: farmaceutska industrija; istraživanje lijekova; razvoj lijekova; prediktivni alati; in silico probir; in vitro probir; terapijski ciljevi
